Expression Levels of RAD51 Inversely Correlate with Survival of Glioblastoma Patients

Dose-intensified chemoradiation is associated with altered patterns of failure and favorable survival in patients with newly diagnosed glioblastoma

(2019) Michelle M. Kim et al.   JOURNAL OF NEURO-ONCOLOGY

Cell quiescence correlates with enhanced glioblastoma cell invasion and cytotoxic resistance

(2018) Ryan J. Atkins et al.   EXPERIMENTAL CELL RESEARCH

RAD51 as a potential surrogate marker for DNA repair capacity in solid malignancies

(2017) Mariam Gachechiladze et al.   INTERNATIONAL JOURNAL OF CANCER

NovoTTF: where to go from here?

(2017) Timothy F. Cloughesy et al.   NEURO-ONCOLOGY

RAD51 Is a Selective DNA Repair Target to Radiosensitize Glioma Stem Cells

(2017) Harry O. King et al.   Stem Cell Reports

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

(2016) David N. Louis et al.   ACTA NEUROPATHOLOGICA

A radiosensitizing effect of RAD51 inhibition in glioblastoma stem-like cells

(2016) Anaïs Balbous et al.   BMC CANCER

Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer

(2016) Bernard Omolo et al.   BMC Medical Genomics

DNA repair mechanisms and their clinical impact in glioblastoma

(2016) Hélène Erasimus et al.   MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH

NanoStringDiff: a novel statistical method for differential expression analysis based on NanoString nCounter data

(2016) Hong Wang et al.   NUCLEIC ACIDS RESEARCH

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma

(2015) Roger Stupp et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial

(2015) Thomas Sandmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors

(2015) Jeanette E. Eckel-Passow et al.   NEW ENGLAND JOURNAL OF MEDICINE

NCBI GEO: archive for functional genomics data sets—update

(2012) Tanya Barrett et al.   NUCLEIC ACIDS RESEARCH

mRNA transcript quantification in archival samples using multiplexed, color-coded probes

(2011) Patricia P Reis et al.   BMC BIOTECHNOLOGY

Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells

(2011) S. C. Short et al.   NEURO-ONCOLOGY

The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombination

(2011) Helen Zhao et al.   RADIOTHERAPY AND ONCOLOGY

Glioblastoma, Cancer Stem Cells and Hypoxia

(2010) Eli E. Bar   BRAIN PATHOLOGY

The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype

(2010) John M. Heddleston et al.   CELL CYCLE

Abstracts from the 9th Meeting of The European Association of NeuroOncology, September 16-19, 2010, Maastricht, The Netherlands

(2010)   NEURO-ONCOLOGY

Rad51 Protein Expression and Survival in Patients with Glioblastoma Multiforme

(2009) James W. Welsh et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells

(2009) James W Welsh et al.   Radiation Oncology

RNA expression analysis from formalin fixed paraffin embedded tissues

(2008) Susan M. Farragher et al.   HISTOCHEMISTRY AND CELL BIOLOGY

Direct multiplexed measurement of gene expression with color-coded probe pairs

(2008) Gary K Geiss et al.   NATURE BIOTECHNOLOGY